Molecular Partners Stock Quote 0QXX - Stock Price, News, Charts, Message Board, Trades

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
UK
LSE
Molecular Partners Ag (0QXX) Quote

Molecular Partners Ag (0QXX)

25.20

0.00

(0.00%)

Closed July 16 11:30AM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Current Price

25.20

Bid

0.00

Ask

0.00

Volume

0.00

0.00 Day's Range 0.00

25.20 52 Week Range 25.20

Market Cap

Previous Close

25.20

Open

-

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

1,206

Shares Outstanding

36,354,000

Dividend Yield

-

PE Ratio

-3.82

Earnings Per Share (EPS)

-1.71

Revenue

7.04M

Net Profit

-61.98M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.molecularpartners.com

Headquarters

Schlieren, Che

Founded

1970

Molecular Partners Ag is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QXX. The last closing price for Molecular Partners was CHF25.20. Over the last year, Molecular Partners shares have traded in a share price range of CHF 25.20 to CHF 25.20.

Molecular Partners currently has 36,354,000 shares outstanding. The market capitalization of Molecular Partners is CHF916.12 million. Molecular Partners has a price to earnings ratio (PE ratio) of -3.82.

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of...

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 MP0712, a 212Pb-Radio-DARPin targeting DLL3, as...

Life Science Cares Launches in Switzerland

Life Science Cares Launches in Switzerland First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	25.2	25.2	25.2	1055	25.2	DE
4	0	0	25.2	25.2	25.2	1086	25.2	DE
12	0	0	25.2	25.2	25.2	1206	25.2	DE
26	0	0	25.2	25.2	25.2	1093	25.2	DE
52	0	0	25.2	25.2	25.2	5600	25.2	DE
156	0	0	25.2	25.2	25.2	9557	25.2	DE
260	0	0	25.2	25.2	25.2	6954	25.2	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
SHOTWSafety Shot Inc	$ 0.41 (115.79%)	7.56k
DATSDatChat Inc	$ 1.89 (81.73%)	54.75M
CYNCYNGN Inc	$ 9.18 (53.77%)	17.79M
SCNIScinai Immunotherapeutics Ltd	$ 5.80 (42.86%)	29.37M
ASLNASLAN Pharmaceuticals Ltd	$ 1.36 (-46.67%)	1.16M
KZIAKazia Therapeutics Ltd	$ 0.5593 (-37.56%)	15.34M
LCFYLocafy Ltd	$ 3.5597 (-36.32%)	584.38k
NAASNaaS Technology Inc	$ 2.82 (-33.02%)	1.94M
ZENVZenvia Inc	$ 1.67 (-26.75%)	658.26k
FFIEFaraday Future Intelligent Electric Inc	$ 0.5152 (22.09%)	217.92M
NVDANVIDIA Corporation	$ 128.44 (-0.62%)	208.32M
SQQQProShares UltraPro Short QQQ	$ 7.46 (-0.67%)	155.14M
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
TSLATesla Inc	$ 252.64 (1.78%)	147.31M

PickStocks

PickStocks 6 minutes ago

That would be awesome as it would be an opportunity to buy more as it goes up again

PickStocks

PickStocks 8 minutes ago

Yes…and he also said real soon months ago

Fdc4

Fdc4 16 minutes ago

I guess you are about to have some proof of your own by now. Ouch… Averaging down now, right? Buying the cheapies

GVInvestments

GVInvestments 18 minutes ago

I'm holding till $300.00 per share.

HippyTrades

HippyTrades 18 minutes ago

Your head is literally spinning because you know that was a horrible annual report and you can't face it

vinmantoo

vinmantoo 21 minutes ago

No data on clinical endpoints.

Thanks for the link. Pretty telling that they didn't include symptom relief data.

HippyTrades

HippyTrades 22 minutes ago

The buyback fund?
Wow do you ever make stuff up.
What do you think a disclosure is?

DocLee

DocLee 23 minutes ago

In "Nature", (12th July) another effective treatment (Car-T) for brain tumours (this time in children) which might complement DCVax (and would be less toxic). The article is at https://www.nature.com/articles/d41586-024-02255-2?utm_source=Live+Audience&utm_campaign=f8586bf0ce-nature-briefing-daily

Wise Man

Wise Man 28 minutes ago

Error in the hyperlink to the CFR 1229.13 posted before, that inserted a new capital distribution: the Lamberth rebate (Number 3), thanks to an express grant of authority of FHFA in the law to do it (Number 3 in the FHEFSSA definition of capital distribution, posted before).
Chevron deference

nowwhat2

nowwhat2 31 minutes ago

1 HR LATER.......

https://investorshub.advfn.com/uimage/uploads/2024/7/16/qtmkceth_777_15_5d_945pm_chan_3500_Gee.jpg

1 HR LATER.......WHUMP !
https://investorshub.advfn.com/uimage/uploads/2024/7/16/facjveth_777_15_5d_1045pm_chan_3500_WHUMP.jpg

nowwhat2

nowwhat2 32 minutes ago

1 HR LATER.......

https://investorshub.advfn.com/uimage/uploads/2024/7/16/qtmkceth_777_15_5d_945pm_chan_3500_Gee.jpg

1 HR LATER.......WHUMP !
https://investorshub.advfn.com/uimage/uploads/2024/7/16/facjveth_777_15_5d_1045pm_chan_3500_WHUMP.jpg

Sltan

Sltan 34 minutes ago

Sltan

Sltan 35 minutes ago

I hope we see
0.01
Earnings results
Fusion
to divide
Million profits
Price 0.0001
Chance of achieving x100
🤑🤑🤑🤑🤑🤑

sentiment_stocks

sentiment_stocks 40 minutes ago

And if your feeling particularly brave, why not contact the Chair of the CHM ?..

p.mulholland@ucl.ac.uk

You know that it was Paul Mullholland who presented the DCVax-L P3 data results at New York Academy of Sciences in about an hour long presentation on May 20, 2023, ri

cootcat

cootcat 42 minutes ago

60f1 you just show up to let us know this is a scam. ARE you new or just a different name? But you are not the first to make that statement or that claim. One has to remember that this is micro penny stock. How many micro pennies stock are call scams and actual are?

rikkie

rikkie 45 minutes ago

BugStrong

BugStrong 48 minutes ago

Today we shall see how the flow is.

LazyInvestor

LazyInvestor 50 minutes ago

What do you mean? The only financial records they needed to be current were for the 10Q for Q1 which were due in May. Or am I missing something here?

BugStrong

BugStrong 53 minutes ago

I thought more info on the companies in the incubator would have been talked, more details.

Louinjaxxx

Louinjaxxx 54 minutes ago

Maybe you don't want the company to audit the lndustries the company is involved in because it could make the company a great find in OTCMarkets.

Maybe you don't like how the CEO is managing the company because you think you could do better (CEO- envy).

Wise Man

Wise Man 56 minutes ago

Summary of the current state of Fanniegate: Chevron deference🆚Rogues.

Justice Alito can't make laws. What he was doing with his opinion, was to endorse the Separate Account plan, whether he likes it or not. His spin isn't even taken into consideration: "Rehabilitate FnF in a w

Twister

Twister 56 minutes ago

Military AR perhaps brighter than events/delays have appeared!

Delayed acceptance, budgets and depth of product scope remain attractive.
Corporate belt tightening is very real and military training budget cuts likely to continue.

Seeing continued interest by othe

Fdc4

Fdc4 60 minutes ago

I wouldn’t be surprised if it is higher. JFHE posted Q2 coming and strong. So, it shall be higher at least. What I don’t understand is why name change is taking too long

Louinjaxxx

Louinjaxxx 1 hour ago

It depends...which do you prefer, 62 mil debt or 31 mil debt?

conix

conix 1 hour ago

Things are really looking up for Biden to roll over Trump in November.

Stay Positive. Biden did GREAT in that Lester Holt interview this evening. Sharp as a tack.

Molecular Partners

Marwyn Value Investors

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions